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Late onset heart failure after childhood
chemotherapy
Improved oncology treatment has dramatically increased the number
5 of long-term cancer survivors, but the potential cardiovascular side
effects from the cancer treatment are increasing their morbidity and
premature mortality.1 This is particularly true for paediatric cancers
patients who are commonly treated with anthracycline chemother-
apy (AC) and/or radiotherapy to the chest (RT), because the devel-
10 oping children’s heart appears more sensitive to the cardiotoxic
effects.2,3 Acute (early-onset) AC-induced cardiotoxicity (AIC) inter-
feres with optimal cancer treatment if interruptions or changes to
cancer treatment are required.
However, for paediatric cancer survivors the major clinical prob-
15 lem is cardiovascular disease years after treatment [late-onset cardio-
toxicity (LOC)]. Second malignancies are also more common in
paediatric cancer survivors, further increasing the risk for additional
cardiotoxic cancer therapies in patients with prior cardiac injury.4
Late heart failure following anthracyclines is particularly treatment-
20resistant and is associated with a poor prognosis. Therefore, recent
guidelines recommend lifelong follow-up of paediatric cancer survi-
vors and especially of those at risk for cardiovascular toxicity.5
Currently, the clinical approach is to treat heart failure after it has
presented. However, if we can develop an improved understanding
25of the molecular pathophysiology then the opportunity to treat and
prevent heart failure in cancer survivors becomes a new option. In
this regard, toxic mitochondria iron accumulation is induced by AC
in cardiomyocytes and dexrazoxane has been shown to protect car-
diomyocytes from doxorubicin induced toxicity (Figure 1).6
Figure 1 Mitochondria with and without Iron.
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.Dexrazoxane has recently been approved for use in paediatric
patients7 and a recent systematic review in paediatric cancer survi-
vors treated with anthracyclines suggests that administration of dex-
razoxane may also reduce LOC.8
5 The dose of AC and/or RT, the patient’s age and cancer type,
treatment duration, and disease relapse are risk factors for LOC.8
There is no proven diagnostic test to identify patients with higher risk
LOC prior its clinical manifestation, although emerging data suggests
reduction in global longitudinal strain on speckle echocardiography in
10 paediatric cancer survivors may precede heart failure presentation.
Furthermore, also knowledge on additional ‘second hit’ risk factors
that may trigger clinical manifestation of LOC.
In addition to the risk associated with the growing heart in chil-
dren, genetic risk factors may play an important role. These include
15 cardiomyopathy-related genes or therapy-induced changes in meta-
bolic pathways leading to prolonged and/or higher serum concentra-
tions of toxic chemotherapeutic substances. Genome-wide
association studies have shown variants in the retinoic acid receptor
gamma (rarg), cugbp elav-like family member 4 (celf4) as possible genet-
20 ic factors predisposing to cardiac damage following anthracycline
therapy.9,10 Several other studies have focused on the identification
of genetic predictors using a candidate gene-based approach11 show-
ing for example that polymorphism in the carbonyl reductase genes
(cbr3)12 and (cbr4),3 electron transfer flavoprotein beta subunit (etfb),13 G
25 protein-coupled receptor 35 (gpr35),14 and hyaluronan synthase 3
(has3)3 may influence genetic predisposition for LOC in paediatric
cancer survivors.
Recent work has demonstrated that human induced pluripotent
stem cell-derived cardiomyocytes (hiPSC-CM) accurately recapitu-
30 late a patient’s predisposition to AIC.15 This exciting finding confirms
that AIC has a genomic basis and that hiPSC-CM can be used for elu-
cidating the genetic variants responsible. In addition, genetic predis-
position to tumour disease may also impact on the risk for LOCM.AQ1
For example, the tumour suppressor breast cancer1 (brca1), which is
35 mutated in early onset familial breast and ovarian cancer and plays an
important role in DNA repair mechanisms of the cardiomyocyte.16
Mutations in such genes may on the one hand lead to cancer but may
also affect the response of the cardiomyocyte to cardiotoxic treat-
ment, as it may play a role in anti-tumour therapy induced damage
40 and damage repair, thereby modulate the risk for LOC. It has also
been demonstrated that erythropoietin may promote repair mecha-
nisms in the heart, especially in cardiac progenitor cells,17 thereby re-
duce the risk for LOC. Recent findings indicate that specific pathways
including PI3Kc, can be up-regulated in the heart after anthracycline
45 therapy and may contribute to heart failure development which not
only involve cardiomyocytes but also inflammatory cells (leucocytes),
thus potentially providing a new strategy to develop biomarkers for
AIC and LOC risks.18
Lifestyle measures are also important factors determining the risk
50 for late onset cardiotoxicity. For example, exercise is beneficial in
cancer patients during and after chemotherapy and may reduce the
risk for LOC.19 This is particularly important as childhood cancer sur-
vivors are less physically active than the general population and adult
survivors are more likely to report a sedentary lifestyle than their sib-
55lings.20 In addition, future cardiovascular stress insults may trigger car-
diovascular disease at a lower threshold in patients previously
treated with cardiotoxic chemotherapy or RT.
One common and important issue specifically for female paediat-
ric cancer survivors, especially with the advances in oocyte preser-
60vation and reproductive science, is pregnancy. Pregnancy induces
high mechanical and neurohormonal stress on the maternal cardio-
vascular system and needs complex signalling networks to prevent
damage of the heart.21 Impairment of these cardioprotective net-
works, which includes pathways typically targeted by anti-cancer
65treatment, such as Vascular Endothelial Growth Factor A (VEGFA),
Signal Transducer And Activator Of Transcription 3 (STAT3), or
Neuregulin-1 (Nrg1) signalling, lead to peripartum cardi-
omyopathy.22 Indeed, there is accumulating evidence that anti-
cancer treatment could predispose women for peripartum heart
70failure later in life.23,24
The appearance of AIC and LOC in cancer survivors together
with the complexity of acute cardiovascular toxicity frommany novel
cancer therapies has led to the development of cardio-oncology as a
new medical subspecialty, with specialist cardio-oncology centres
75created to address this growing medical problem.25 New strategies
to detect toxicity earlier with sensitive cardiac biomarkers and imag-
ing are being implemented.26 However, to date the molecular mecha-
nisms of late onset cardiotoxicity are incompletely understood and
no biomarkers are available for monitoring and prediction for LOC
80disease risk and no approved specific co-treatments to prevent LOC
are available. Exploring both the mechanisms of acute and long-term
cardiovascular side effects of anti-tumour therapies, to develop early
markers and preventive and curative treatment is needed not only to
reduce cancer disease but to improvemorbidity and mortality of can-
85cer survivors.
We believe this can be achieved by combined interdisciplinary
efforts of clinicians and scientist from oncology and cardiology work-
ing together in cardio-oncology science.
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